A Phase 2 interventional study of KRT-232 and Ruxolitinib in Polycythemia Vera, sponsored by Kartos Therapeutics, Inc.. Status unknown at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.
Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Polycythemia Vera with a site in United States — 21 open to participants now, 33 under way, 7 of them phase 3. Polycythemia Vera · United States.
Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 111th largest by enrollment of the 150 interventional ones that give a count, is one of 7 that started in 2019, is one of 68 in phase 2, and was the 138th registered.
279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →21 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Canada, Israel
Ages 18+
Massachusetts General Hospital · Sites in United States
Healthy volunteers
Ono Pharmaceutical Co., Ltd. · Sites in United States, Australia, Austria and 6 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 61 · Phase 2 89 · Phase 3 20
First in 1992; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 52 across 205 interventional studies indexed under Polycythemia Vera.
Median enrollment 40 across the 150 interventional studies, 678 across the 15 observational. Of the 135 that completed or were terminated, 54 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 179 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kartos Therapeutics, Inc., one of the names counted as Ipsen. Under that name alone:
Kartos Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 7 are open to participants now.
Ipsen has 1 study filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
9 of the studies in Polycythemia Vera with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07203768FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSA ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies in Polycythemia Vera with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to hydroxyurea or have undergone treatment with interferon. In Part B, patients must be resistant or intolerant to hydroxyurea.
This study is a global, open-label Phase 2a/2b study to determine the efficacy and safety of KRT-232. In Part A of the study, patients will be randomly assigned to 5 arms with 2 different doses and 3 different dosing schedules of KRT 232. In Part B of the study, patients will be randomized either to treatment with KRT-232 administered at the recommended dose and schedule from Part A or to treatment with ruxolitinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Drug: KRT-232
KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Drug: KRT-232
KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
Drug: KRT-232
Recommended KRT-232 dose and schedule from Part A
Drug: KRT-232
Ruxolitinib per approved prescribing label
Drug: Ruxolitinib
KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
Drug: KRT-232
KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
Drug: KRT-232
KRT-232, administered by mouth
Ruxolitinib per approved prescribing label
Proportion of patients with splenomegaly achieving a response at Week 32
Response defined as having achieved both of the following: * The absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32, with no more than one phlebotomy eligibility occurring post-randomization and prior to the Week 8 visit * A reduction in spleen volume as assessed by MRI (or CT) ≥ 35% from baseline at Week 32
Time frame: 32 weeks
Duration of response after achieving both the absence of phlebotomy eligibility and reduction in spleen volume (for patients with splenomegaly)
Time frame: 4 years
Duration of response after achieving phlebotomy independence
Time frame: 4 years
Change from baseline of MPN-SAF TSS v2.0 patient-reported outcome
Time frame: 32 weeks
Change from baseline of EORTC-QLQ-C30 patient-reported outcome
Time frame: 32 weeks
Proportion of patients without splenomegaly achieving the absence of phlebotomy eligibility beginning at the Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8
Time frame: 28 weeks
Started Jan 2019 (actual). Primary completion is estimated for Apr 2022, 39 months after the start.
Of 43 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's planned 39 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navtemadlin